You are here

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Work disability and health-related quality of life in males and females with psoriatic arthritis
  1. M Wallenius1,2,
  2. J F Skomsvoll1,2,
  3. W Koldingsnes3,
  4. E Rødevand1,
  5. K Mikkelsen4,
  6. C Kaufmann5,
  7. T K Kvien6,7
  1. 1
    Department of Rheumatology, Trondheim University Hospital, Trondheim, Norway
  2. 2
    Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
  3. 3
    Department of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
  4. 4
    Department of Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
  5. 5
    Department of Rheumatology, Buskerud Central Hospital, Drammen, Norway
  6. 6
    Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  7. 7
    Faculty of Medicine, University of Oslo, Oslo, Norway
  1. Dr M Wallenius, Department of Rheumatology, St Olav’s Hospital, Trondheim University Hospital, Olav Kyrres gt 17, N-7006 Trondheim, Norway; marianne.wallenius{at}ntnu.no

Abstract

Objectives: To compare health status, demographic variables and work disability (WD) between males and females with psoriatic arthritis (PsA) in the 18–45 age group, and further to compare health status between those with and without WD for each gender and to identify variables associated with WD.

Methods: A cross-sectional study was carried out of patients with PsA with peripheral arthritis at the time at which they started disease-modifying antirheumatic drug therapy (DMARD) and/or biological treatment. Patients receiving a permanent national WD pension corresponding to ⩾50% were defined as work disabled. Gender differences were examined with regard to health status, demographic variables and WD. Mann–Whitney U test and Pearson χ2 were applied for group comparisons between males and females and work disabled versus not work disabled for each gender. Multiple logistic regression analyses with adjustments for duration of education, disease duration, age, erosive disease, disability score (Modified Health Assessment Questionnaire; MHAQ), the short form-36 (SF-36) mental health score, and gender were used to identify variables associated with WD.

Results: Out of 271 (102 females) patients, the number (%) of work-disabled females/males was 33 (32.7%)/29 (17.4%) (p = 0.004). Work-disabled patients had generally worse health status than non-work-disabled patients, and these differences were generally more pronounced in males than in females. In the multiple logistic regression model, low educational level, increasing disability score (MHAQ), presence of erosive disease, female gender and disease duration were independently associated with WD.

Conclusions: WD in patients with PsA below 45 years of age was independently associated with educational level, disability score, erosive disease, female gender and disease duration.

https://doi.org/10.1136/ard.2008.092049

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: MW has received speaker honoraria from Abbott, JFS has received speaker honoraria from Wyeth, CK reports no conflicts of interest, KM has received speaker honoraria from Abbott, ER has received investigator honoraria from Abbott, WK has received speaker honoraria from different pharmaceutical companies, including Abbott, Wyeth and Schering Plough, TKK has received research grants and honoraria as a speaker and consultant from several pharmaceutical companies, including Abbott, Schering-Plough and Wyeth.

    • Funding: Research grants for the NOR-DMARD study have been received from Abbott, Amgen, Aventis, MSD, Schering-Plough/Centocor, Wyeth and the Norwegian Directorate for Health and Social Affairs. This actual work was supported by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU)

    • Ethics approval: The study had been evaluated by the Norwegian Data Inspectorate, the regional ethical committee and the drug regulatory authorities.

    • Patient consent: Obtained.